Allena Pharmaceuticals, Inc. Debt/Assets

Debt/Assets of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Debt/Assets for the quarter ending March 31, 2022 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Assets decreased by -100.0%
  • Annual Debt/Assets for 2021 was 29.86% (a 10.39% increase from previous year)
  • Annual Debt/Assets for 2020 was 27.05% (a -12.06% decrease from previous year)
  • Annual Debt/Assets for 2019 was 30.76% (a 101.05% increase from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of Allena Pharmaceuticals, Inc.

Most recent Debt/Assetsof ALNA including historical data for past 10 years.

Interactive Chart of Debt/Assets of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0%
2021 29.86% 23.86% 34.74% 25.88% 29.86%
2020 27.05% 31.4% 28.45% 39.75% 27.05%
2019 30.72% 17.57% 15.87% 17.32% 30.76%
2018 15.3% 13.59% 12.46% 5.18% 15.3%
2017 5.73% 18.26% 0.0% 0.0% 9.75%
2016 0.0% 0.0% 19.37%
2015 5.61% 5.62%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.